Polymorphic and other crystalline forms of cis-FTC

Details Polymorphic and other crystalline forms of cis-FTC Polymorphic and other crystalline forms of cis-FTC

2004-04-19

2009-06-09

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S317000

Reexamination Certificate

active

07544692

ABSTRACT:
Solid phases of (−)-cis-FTC, which are designated herein as amorphous (−)-FTC and Forms II and III (−)-cis-FTC) are provided that can be distinguished from Form I (−)-cis-FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. A hydrated crystalline form of (±)-cis-FTC (i.e. racemic cis-FTC), and a dehydrated form of the hydrate, are also provided, and can similarly be distinguished from other forms of FTC by X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These FTC forms can be used in the manufacture of other forms of FTC, or in pharmaceutical compositions. Particularly preferred uses of these forms are in the treatment of HIV or hepatitis B.

REFERENCES:
patent: 4476248 (1984-10-01), Gordon et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5041449 (1991-08-01), Belleau et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5075445 (1991-12-01), Jarvest et al.
patent: 5142051 (1992-08-01), Holy et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5234913 (1993-08-01), Furman, Jr. et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5272151 (1993-12-01), Marzi et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5538975 (1996-07-01), Dionne
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5618820 (1997-04-01), Dionne
patent: 5641763 (1997-06-01), Holy et al.
patent: 5663320 (1997-09-01), Mansour et al.
patent: 5674849 (1997-10-01), Twist et al.
patent: 5684010 (1997-11-01), Schinazi
patent: 5684153 (1997-11-01), Geen et al.
patent: 5684164 (1997-11-01), Belleau et al.
patent: 5693787 (1997-12-01), Mansour et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5700937 (1997-12-01), Liotta et al.
patent: 5728575 (1998-03-01), Liotta et al.
patent: 5744596 (1998-04-01), Mansour et al.
patent: 5756478 (1998-05-01), Cheng et al.
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5763606 (1998-06-01), Mansour et al.
patent: 5767122 (1998-06-01), Chu et al.
patent: 5808040 (1998-09-01), Chu et al.
patent: 5814639 (1998-09-01), Liotta et al.
patent: 5827727 (1998-10-01), Liotta et al.
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5892025 (1999-04-01), Liotta et al.
patent: 5905082 (1999-05-01), Roberts et al.
patent: 5914331 (1999-06-01), Liotta et al.
patent: 5922867 (1999-07-01), Mansour et al.
patent: 6071922 (2000-06-01), Schinazi et al.
patent: 6177435 (2001-01-01), Larder et al.
patent: 6228860 (2001-05-01), Mansour et al.
patent: 6600044 (2003-07-01), Murthy et al.
patent: 6642245 (2003-11-01), Liotta et al.
patent: 6703396 (2004-03-01), Liotta et al.
patent: 6723728 (2004-04-01), Hu et al.
patent: 0 141 927 (1984-08-01), None
patent: 0 253 412 (1987-07-01), None
patent: 0 337 713 (1989-04-01), None
patent: 0 382 526 (1990-02-01), None
patent: 0 711 771 (1990-02-01), None
patent: 0 513 200 (1991-01-01), None
patent: 0 494 119 (1992-01-01), None
patent: 0 515 144 (1992-05-01), None
patent: 0 517 145 (1992-06-01), None
patent: WO 89/02733 (1988-09-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 91/16920 (1991-04-01), None
patent: WO 91/17159 (1991-05-01), None
patent: WO 91/18914 (1991-05-01), None
patent: WO 91/19721 (1991-06-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 92/18517 (1992-04-01), None
patent: WO 92/10497 (1992-06-01), None
patent: WO 92/14743 (1992-09-01), None
patent: WO 92/21676 (1992-12-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 94/04154 (1994-03-01), None
patent: WO 94/09793 (1994-05-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 95/20595 (1995-01-01), None
patent: WO 95/29174 (1995-04-01), None
patent: WO 98/23285 (1998-06-01), None
patent: WO 00/09494 (2000-02-01), None
patent: WO 00/22157 (2000-04-01), None
patent: WO 02/070518 (2002-09-01), None
Chang, C.-N., et al., “Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′.3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication,”J. Biol. Chem., 267(20):13938-13942 (1992).
Choi, W.-B., et al., “In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of oxathiolanyl and dioxolanyl nucleoside analogues,”J. Am. Chem. Soc.,113(24):9377-9379 (1991).
DaVisson, V.J., et al., “Synthesis of Nucleotide 5′-Diphosphates from 5′-O-Tosyl Nucleosides,”J. Org. Chem.,52(9):1794-1801 (1987).
Furman, P.A., et al., “The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers ofcis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine”Antimicrobial Agents and Chemotherapy, 36(12):2686-2692 (Dec. 1992).
Hoard, D.E., et al., “Conversion of Mono- and Oligodeoxyribonucleotides to 5′-Triphosphates,”J. Am. Chem. Soc., 87(8):1785-1788 (Apr. 20, 1965).
Imai, K., et al., “Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides.”J. Org. Chem.,34(6):1547-1550 (Jun. 1969).
International Search Report for WO02/070518, dated Jul. 23, 2002.
Jones, R.J., et al., “Mini Review: Nucleotide prodrugs,”Antiviral Research, 27:1-17 (1995).
Jozwiakowski, M.J., et al., “Solubility Behavior of Lamivudine Crystal Forms in Recrystallization Solvents”,J. Pharm. Sci., 85(2):193-199 (1996).
Korba et al., “Penciclovir is a Selective Inhibitor of Hepatitis B Virus Replication in cultured Human Hepatoblastoma Cells,”Antimicrobial Agents and Chemotherapy, Abstract (1996).
Korba et al.; “Use of a Standardized Cell Culture Assay to Assess Activities of Nucleoside Analogs Angainst Hepatitis B Virus Replication,”Antiviral Research, (1992):55-70.
Korba, Brent E., “In Vitro Evaluation of Combination Therapies Against Hepatitis B Virus Replication,”Antiviral Research, (1995):49-51.
Kruger et al.. “Treatment of Hepatitis B-related Polyarteritis Nodosa with Famciclovir and Interferon Alfa-2b,”Journal of Hepatology, Abstract (1997).
Migyoung et al.; “Dioxolane Cytosine Nucleosides as Anti-Hepatitis B Agents,”Bioorganic&Medicinal Chemistry Letters; 5(17):2011-2014 (1995).
Norbeck, D. W. et al., “A new 2′,3′-dideoxynucleoside prototype with in vitro activity against HIV,”Tetrahedron Letters, 30(46):6263-6266 (1989).
Schinazi, R.F., et al., “Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers ofcis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl] Cytosine,”Antimicrobial Agents and Chemotherapy, 36(11):2423-2431 (Nov. 1992).
Von Janta-Lipinski, M., et al., “Newly Synthesized L-Enantiomers of 3′-Fluoro-Modified β-2′-Deoxyribonucleoside 5′-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular DNA Polymerases α, β, γ, δ, and ε Nor HIV-1 Reverse Transcriptase,”J. Med. Chem.,41(12):2040-2046 (May 21, 1998).

Affiliated with

Also associated with

Rating

Polymorphic and other crystalline forms of cis-FTC does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphic and other crystalline forms of cis-FTC, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphic and other crystalline forms of cis-FTC will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4079004